We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Best Options Trade for Gilead Sciences (GILD) Earnings
Read MoreHide Full Article
On Tuesday, November 1st, Gilead Sciences (GILD - Free Report) will release its third quarter earnings results after the bell. The company is a Zacks Rank 5 (Strong Sell), and have a Value, Growth, and Momentum score of B.
Dave will look at Gilead Sciences’ past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Gilead Sciences ahead of earnings.
Gilead Sciences in Focus
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
Gilead Sciences is expected to report earnings at $2.74 a share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 0.33% at $3.03 per share, beating estimates of $3.02 a share.
Gilead Sciences is trading around $73 a share, and their 52-week high is $110.77 per share. Their average EPS surprise is 1.66%.
Bottom Line
How should investors play Gilead Sciences ahead of their earnings report? For insights on the best options trades, then make sure you tune in on our YouTube channel at 1pm to see his thoughts!
Confidential from Zacks
Would you like to access Zacks' 2 best trades that are not available to the public? Zacks Executive VP, Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered. Today he is prepared to pass the Best of Our Best along to you. See these timely buys now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Best Options Trade for Gilead Sciences (GILD) Earnings
On Tuesday, November 1st, Gilead Sciences (GILD - Free Report) will release its third quarter earnings results after the bell. The company is a Zacks Rank 5 (Strong Sell), and have a Value, Growth, and Momentum score of B.
Dave will look at Gilead Sciences’ past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Gilead Sciences ahead of earnings.
Gilead Sciences in Focus
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
Gilead Sciences is expected to report earnings at $2.74 a share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 0.33% at $3.03 per share, beating estimates of $3.02 a share.
GILEAD SCIENCES Price, Consensus and EPS Surprise
GILEAD SCIENCES Price, Consensus and EPS Surprise | GILEAD SCIENCES Quote
Gilead Sciences is trading around $73 a share, and their 52-week high is $110.77 per share. Their average EPS surprise is 1.66%.
Bottom Line
How should investors play Gilead Sciences ahead of their earnings report? For insights on the best options trades, then make sure you tune in on our YouTube channel at 1pm to see his thoughts!
Confidential from Zacks
Would you like to access Zacks' 2 best trades that are not available to the public? Zacks Executive VP, Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered. Today he is prepared to pass the Best of Our Best along to you. See these timely buys now >>